Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.59 |
| ▸ | EGFR | P00533 | 3/20 | 0.59 |
| ▸ | RET | P07949 | 3/20 | 0.59 |
| ▸ | STK10 | O94804 | 1/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | YES1 | P07947 | 1/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.59 |
| ▸ | BCR | P11274 | 1/20 | 0.59 |
| ▸ | FLT1 | P17948 | 1/20 | 0.59 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.59 |
| ▸ | WEE1 | P30291 | 1/20 | 0.59 |
| ▸ | ABL2 | P42684 | 1/20 | 0.59 |
| ▸ | NEK3 | P51956 | 1/20 | 0.59 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.59 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.59 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.59 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.59 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4763956 | 0.93 | KDR (0.50) | KDRERBB2EGFRRETSTK10 | |
| SCHEMBL4766961 | 0.90 | CSF1R (0.61) | KDRERBB2EGFRRETSTK10 | |
| SCHEMBL4770678 | 0.88 | KDR (0.59) | KDRERBB2EGFRRETSTK10 | |
| SCHEMBL4764050 | 0.87 | EGFR (0.58) | KDRERBB2EGFRRETSTK10 | |
| SCHEMBL4770592 | 0.85 | RET (0.48) | EGFRRETCSF1RKIT | |
| SCHEMBL4769675 | 0.83 | CHUK (0.48) | EGFRRETCSF1R | |
| SCHEMBL4766319 | 0.83 | CSF1R (0.54) | EGFRRETCSF1R | |
| SCHEMBL4766999 | 0.81 | EGFR (0.62) | KDRERBB2EGFRRETSTK10 | |
| SCHEMBL4768480 | 0.81 | KDR (0.59) | KDRERBB2EGFRRETSTK10 | |
| SCHEMBL4773238 | 0.81 | KDR (0.59) | KDRERBB2EGFRRETSTK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390805-B2 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2008-06-24 | — | — | US | claimed |
| EP-1416935-B1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-03-12 | — | — | EP | claimed |
| US-20070161632-A1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | BOLD GUIDO | 2007-07-12 | — | — | US | claimed |
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | BOLD GUIDO (CH) | 2004-12-09 | — | — | US | claimed |
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | claimed |
| EP-1416935-B1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161632-A1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | TYMP, DPYD, CCND2 | KDR 1868/4885ERBB2 539/4885EGFR 1650/4885 |
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | DPYD, DHPS, TYMP | KDR 3031/4885ERBB2 2012/4885EGFR 3391/4885 |
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | DPYD, TYMP, TYMS | KDR 2234/4885ERBB2 1341/4885EGFR 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.